Germany · Delayed Price · Currency is EUR Novakand Pharma AB Statistics
Total Valuation
FRA:3EE0 has a market cap or net worth of EUR 1.36 million. The enterprise value is -143,344.
| Market Cap | 1.36M |
| Enterprise Value | -143,344 |
Important Dates
The last earnings date was Friday, February 20, 2026.
| Earnings Date | Feb 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 121.19M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 112.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,052.45 |
| PB Ratio | 0.98 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.03 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.03
| Current Ratio | 10.03 |
| Quick Ratio | 9.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -122.09% and return on invested capital (ROIC) is -47.82%.
| Return on Equity (ROE) | -122.09% |
| Return on Assets (ROA) | -44.23% |
| Return on Invested Capital (ROIC) | -47.82% |
| Return on Capital Employed (ROCE) | -196.45% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 259 |
| Profits Per Employee | -872,819 |
| Employee Count | 5 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.85% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -99.85% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 48.13 |
| Average Volume (20 Days) | 506 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:3EE0 had revenue of EUR 1,294 and -4.36 million in losses. Loss per share was -3.60.
| Revenue | 1,294 |
| Gross Profit | 1,294 |
| Operating Income | -2.73M |
| Pretax Income | -4.36M |
| Net Income | -4.36M |
| EBITDA | n/a |
| EBIT | -2.73M |
| Loss Per Share | -3.60 |
Balance Sheet
The company has 1.49 million in cash and n/a in debt, with a net cash position of 1.49 million.
| Cash & Cash Equivalents | 1.49M |
| Total Debt | n/a |
| Net Cash | 1.49M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.39M |
| Book Value Per Share | 0.01 |
| Working Capital | 1.39M |
Cash Flow
| Operating Cash Flow | -2.80M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -211,326.82% |
| Pretax Margin | -337,256.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:3EE0 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.08% |
| Shareholder Yield | -5.08% |
| Earnings Yield | -320.45% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 24, 2021. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 24, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |